• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

Supernus Pharma(SUPN.US)

Overview
News
Financials
© 2026 Longbridge|Disclaimer

Event Tracking

Nov21
Supernus CEO to Attend Piper Sandler Healthcare Conference
21:06
Nov5
Supernus Pharma released FY2025 Q3 earnings on November 4 After-Market EST, actual revenue USD 192.1 M (forecast USD 180.22 M), actual EPS USD -0.8 (forecast USD -0.08)
00:00
Supernus Pharma released FY2025 9 Months Earnings on November 4 After-Market EST, with actual revenue of USD 507.38 M and EPS of USD -0.6117
00:00
Nov4
Supernus Pharmaceuticals Announces ONAPRO Supply Constraints and Raises Revenue Guidance
22:21
Supernus Pharmaceuticals Reports Q3 Operating Loss of $60.231 Million
21:01
Oct29
BofA Securities Upgrades Supernus Pharmaceuticals to Buy, Shares Rise
13:04

Schedules & Filings

Schedules
Filings
Nov4
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 192.1 M, Net Income -45.12 M, EPS -0.8

Aug5
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 165.45 M, Net Income 22.5 M, EPS 0.4

May6
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 149.82 M, Net Income -11.83 M, EPS -0.2117

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
INBS
9.530
+132.44%
+5.430
ANGH
3.770
+62.50%
+1.450
WTO
1.020
+61.09%
+0.387
ESHAR
0.2500
+47.06%
+0.080
NCL
0.2731
+40.77%
+0.079
FGMCR
0.5500
+33.50%
+0.138
ESHA
19.180
+33.38%
+4.800
IPEXR
0.8000
+31.97%
+0.194
RDACR
0.2400
+26.32%
+0.050
DVLT
0.6521
+26.25%
+0.136
View More